Genticel is facing hard Times Again!

27/06/2016 - 2 minutes

As presented last week, Genticel was getting back on track with the announcement of two major milestones with the aim to prepare the phase III. However, the major outcomes of its Phase II were expected to be presented on the 17th of June at Eurogin 2016 Congress… Here they are (and they are really bad)!

genticel_hpv_cervical_cancer_vaccineGTL001 is designed to target and clear strain 16 & 18 of the Human Papillomavirus (HPV) from an infected body and avoid the development of cervical cancer, theoretically… Unfortunately, it seems like the treatment has some lack of activity. Indeed, the vaccine did not show any significant difference compared to the placebo.

The Phase II trial enrolled 233 patients – 117 have received two injections of 600 µg vaccines within 6 weeks and 116 the placebo with the same posology. After 18 months results showed that the clearance (elimination of the virus from the body) wasn’t higher in the first group than in the second one.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!